1 / 8

Multiple Sclerosis Therapeutics Market Overview, Business Opportunities future,

The Multiple Sclerosis Therapeutics Market was valued at US$ 24,026.90 million in 2019 and it is projected to reach US$ 39,223.59 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027.<br>

Robert105
Télécharger la présentation

Multiple Sclerosis Therapeutics Market Overview, Business Opportunities future,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Multiple Sclerosis Therapeutics Market Trends, Size, Segments, Emerging Technologies 2027 Published Date : May 2022 Email: sales@theinsightpartners.com

  2. Email:sales@theinsightpartners.com Report Studies • Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce), and Geography

  3. Email:sales@theinsightpartners.com Multiple Sclerosis Therapeutics Market Overview • The Multiple Sclerosis Therapeutics Market was valued at US$ 24,026.90 million in 2019 and it is projected to reach US$ 39,223.59 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027. • Based on drug class, the market is segmented into immunosuppressant and immunomodulators. In 2019, the immunomodulators segment accounted for larger share of the market. Growth of this segment is attributed to launch of new generic drugs and increase in adoption of immunomodulators in multiple sclerosis (MS) treatment. The immunosuppressant segment is likely to register higher CAGR during the forecast period.

  4. Email:sales@theinsightpartners.com Key Segment Market Segment By Type:- • By Drug Class (Immunosuppressant, Immunomodulators And Others) • By Route Of Administration (Injectable, Oral) • By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, E-commerce) Download Sample

  5. Email:sales@theinsightpartners.com Multiple Sclerosis Therapeutics MarketValue CAGR of 6.5% (2020 - 2027) Download Sample

  6. Email:sales@theinsightpartners.com Company Profiles • Merck & Co., Inc. • Novartis AG • Bayer AG • Sanofi • Bristol-Myers Squibb Company • Horizon Therapeutics plc. • TEVA PHARMACEUTICAL INDUSTRIES LTD • Takeda Pharmaceutical Company Limited • F. HOFFMANN-LA ROCHE LTD. • Biogen Download Sample

  7. Email:sales@theinsightpartners.com By Geography • North America (the US, Canada, and Mexico) • Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe) • Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific) • Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa) • South & Central America (Brazil, Argentina, and the Rest of South & Central America).

  8. THANKYOU! Phone : +1-646-491-9876 E-Mail : sales@theinsightpartners.com

More Related